medical decision making. The term evidencebased medicine emerged in the early 1990s to promote clinical practice grounded in evidence rather than experience. But research has since confirmed that more than one "best" option often exists to treat a given condition. For example, patients with earlystage prostate cancer must choose from active surveillance, radical prostatectomy, and radiation type. Thyroid cancer patients must decide whether to undergo radioactive iodine therapy. Whereas the doctor traditionally made such decisions, patients in "preference sensitive" decision making choose for themselves after evaluating risks and benefits. "We owe it to patients to give them data that they can understand," said Angela Fagerlin, Ph. 
:S7).
A larger problem is getting them to patients: "There is no money to disseminate them," Fagerlin said.
Although oncologists who treat breast cancer use PtDAs extensively, physicians treating other illnesses, including other types of cancer, have not embraced these tools. One reason could be oncologists' reluctance to give bad news, Smith said. But "you don't get any bonus survival points for denying the truth," he added. Physicians have also cited having little confidence in the content of such tools as well as concerns about disrupting established workflows, Elwyn said.
Because academics develop most PtDAs, however, physicians associated with academic The PDQ Genetics of Colorectal Cancer and the PDQ Genetics of Prostate Cancer summaries were recently updated to include the results of a study of 198 families in two U.S. Lynch syndrome registries that found an increased cumulative incidence and risk of prostate cancer among Lynch syndrome family members. Prostate cancer risk in relatives of mismatch repair gene mutation carriers was 6.3% at age 60 years and 30% at age 80 years compared with a population risk of 2.6% at age 60 years and 18% at age 80 years, with an overall hazard ratio (HR) of 1.99 (95% confidence interval [CI], 1.31-3.03; P = .0013). Among men aged 20 to 59 years, the HR was 2.48 (95% CI, 1.34-4.59; P = .0038). The authors suggested consideration of prostate cancer screening beginning at age 40 years in male mismatch repair gene mutation carriers, although additional studies are needed to assess the The PDQ Cancer Genetics Risk Assessment and Counseling summary was recently updated to state that advanced training in cancer genetics and genomics is needed among health professionals to increase competency in the following reported areas of deficit: (1) The PDQ Genetics of Skin Cancer summary was recently updated to include a new section on BRCA-associated protein 1 (BAP1), a tumor suppressor gene that has recently been implicated in both sporadic and hereditary melanomas. To review the summary, please use the following link: http://www.cancer.gov/cancertopics/ pdq/genetics/skin/HealthProfessional/ Page4#Section_786
The PDQ Pediatric Cancer Treatment Editorial Board recently completed a major update of the Wilms Tumor and Other Childhood Kidney Tumors Treatment summary. The Board conducted a review of the published literature and revised the text of the summary and updated the citations.
